Identifying the genetic basis of human diseases, where multiple genes contribute only slightly to the diseases state, has been relatively unsuccessful. The entire genome is treated as equally likely to contain members of these disease genes, and therefore contends with billions of nucleotide positions and a very large search space. This paper describes a method of restricting the genomic search space based upon evolutionary arguments of stepwise accumulation of signaling complexity in the human genome, consequently increasing the ability to identify the genetic cause of complex disorders.
FEATURE REVIEW
Phenotype of schizophrenia: a review and formulation
CA Tamminga and HH Holcomb
The clinical phenomenology of schizophrenia with its behavioral presentation, cognitive characteristics and electrophysicologic profile can aptly be called its clinical phenotype. The clinical picture is complex, and no one knows yet how the disease characteristics sort to individual phenotypes that are reflective of a single set of molecular target changes. Several aspects of the phenotype are distinctive and are presumed to be informative about schizophrenia pathophysiology: signs and symptoms, disease course, genetics, cognitive and task-activated brain activation patterns, postmortem tissue characteristics, and schizophrenia pharmacology will all contribute.
Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence PJ Harrison, DR Weinberger
This article begins by summarizing the pathological findings in the brain in schizophrenia and the evidence that the disorder affects the way nerve cells and their synapses are organized. It then reviews the evidence of several identified genes that affect the risk of developing schizophrenia. Finally, it discusses the relationship between genes and pathology, and proposes that all the genes, in one way or another, influence the functioning of particular neural circuits.
Expanding the 'central dogma': the regulatory role of nonprotein coding genes and implications for the genetic liability to schizophrenia DO Perkins, CD Jeffries, P Sullivan
The majority of the human transcriptome is RNA that does not code for a protein (ncRNA). The function of ncRNA includes regulating the rate and timing of protein synthesis. Several newly understood control mechanisms for gene expression are reviewed in this manuscript. The authors discuss how dysregulation of transcription or of translation of a normal gene by ncRNA or other mechanisms may lead to abnormal gene expression, contributing to risk of complex disorders such as schizophrenia.
Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs S Miyamoto, GE Duncan, CE Marx, JA Lieberman Second-generation antipsychotics can offer advantages over first-generation agents such as improvement in negative symptoms, cognitive impairment, relapse prevention, and functional capacity, with fewer extrapyramidal symptoms. Certain side effects associated with second-generation drugs still affect patient health and quality of life, and thus there is a continuing need for better drugs. Aripiprazole has a novel mode of action, and may be a useful addition to our therapeutic armamentarium. This article provides a brief review and critique of current drug development strategies and theories of mechanisms of action of antipsychotic drugs.
The functional neuroanatomy of bipolar disorder: a review of neuroimaging findings SM Strakowski, MP DelBello, CM Adler The authors reviewed current neuroimaging studies to clarify the biological causes of bipolar disorder. These studies suggest that several key brain areas, including the amygdala, parts of the prefrontal cortex and striatum exhibit abnormalities prior to the onset of significant symptoms. Additional brain changes develop over time in bipolar disorder and may signal the progression of the illness. Together, these findings suggest that bipolar disorder arises from abnormalities within brain networks that control emotional homeostasis.
Lithium and bipolar mood disorder: the inositol-depletion hypothesis revisited AJ Harwood Lithium's effect of reducing the intracellular concentration of myoinositol has been known for over 35 years. As an effective mood stabilizer, the therapeutic effects of lithium, and perhaps an underlying cause of the bipolar mood disorder, could arise through altered inositol phosphate signaling. A number of recent results strengthen the link between mood stabilizers and inositol depletion; however, the clinical case is still not proven and other cellular targets of lithium pose alternative mechanisms.
